Eva Heckova, Bernhard Strasser1, Gilbert J Hangel, Michal Považan2,3, Assunta Dal-Bianco4, Paulus S Rommer4, Petr Bednarik, Stephan Gruber, Fritz Leutmezer4, Hans Lassmann5, Siegfried Trattnig6, Wolfgang Bogner6. 1. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Russell H. Morgan Department of Radiology and Radiological Science, The John Hopkins University School of Medicine, Baltimore, MD. 3. F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD. 4. Department of Neurology, and. 5. Center for Brain Research, Medical University of Vienna. 6. Christian Doppler Laboratory for Clinical Molecular MR Imaging, Vienna, Austria.
Abstract
OBJECTIVES: The aim of this study was to assess the utility of increased spatial resolution of magnetic resonance spectroscopic imaging (MRSI) at 7 T for the detection of neurochemical changes in multiple sclerosis (MS)-related brain lesions. MATERIALS AND METHODS: This prospective, institutional review board-approved study was performed in 20 relapsing-remitting MS patients (9 women/11 men; mean age ± standard deviation, 30.8 ± 7.7 years) after receiving written informed consent. Metabolic patterns in MS lesions were compared at 3 different spatial resolutions of free induction decay MRSI with implemented parallel imaging acceleration: 2.2 × 2.2 × 8 mm; 3.4 × 3.4 × 8 mm; and 6.8 × 6.8 × 8 mm voxel volumes, that is, matrix sizes of 100 × 100, 64 × 64, and 32 × 32, respectively. The quality of data was assessed by signal-to-noise ratio and Cramér-Rao lower bounds. Statistical analysis was performed using Wilcoxon signed-rank tests with correction for multiple testing. RESULTS: Seventy-seven T2-hyperintense MS lesions were investigated (median volume, 155.7 mm; range, 10.8-747.0 mm). The mean metabolic ratios in lesions differed significantly between the 3 MRSI resolutions (ie, 100 × 100 vs 64 × 64, 100 × 100 vs 32 × 32, and 64 × 64 vs 32 × 32; P < 0.001). With the ultra-high resolution (100 × 100), we obtained 40% to 80% higher mean metabolic ratios and 100% to 150% increase in maximum metabolic ratios in the MS lesions compared with the lowest resolution (32 × 32), while maintaining good spectral quality (signal-to-noise ratio >12, Cramér-Rao lower bounds <20%) and measurement time of 6 minutes. There were 83% of MS lesions that showed increased myo-inositol/N-acetylaspartate with the 100 × 100 resolution, but only 66% were distinguishable with the 64 × 64 resolution and 35% with the 32 × 32 resolution. CONCLUSIONS: Ultra-high-resolution MRSI (~2 × 2 × 8 mm voxel volume) can detect metabolic alterations in MS, which cannot be recognized by conventional MRSI resolutions, within clinically acceptable time.
OBJECTIVES: The aim of this study was to assess the utility of increased spatial resolution of magnetic resonance spectroscopic imaging (MRSI) at 7 T for the detection of neurochemical changes in multiple sclerosis (MS)-related brain lesions. MATERIALS AND METHODS: This prospective, institutional review board-approved study was performed in 20 relapsing-remitting MS patients (9 women/11 men; mean age ± standard deviation, 30.8 ± 7.7 years) after receiving written informed consent. Metabolic patterns in MS lesions were compared at 3 different spatial resolutions of free induction decay MRSI with implemented parallel imaging acceleration: 2.2 × 2.2 × 8 mm; 3.4 × 3.4 × 8 mm; and 6.8 × 6.8 × 8 mm voxel volumes, that is, matrix sizes of 100 × 100, 64 × 64, and 32 × 32, respectively. The quality of data was assessed by signal-to-noise ratio and Cramér-Rao lower bounds. Statistical analysis was performed using Wilcoxon signed-rank tests with correction for multiple testing. RESULTS: Seventy-seven T2-hyperintense MS lesions were investigated (median volume, 155.7 mm; range, 10.8-747.0 mm). The mean metabolic ratios in lesions differed significantly between the 3 MRSI resolutions (ie, 100 × 100 vs 64 × 64, 100 × 100 vs 32 × 32, and 64 × 64 vs 32 × 32; P < 0.001). With the ultra-high resolution (100 × 100), we obtained 40% to 80% higher mean metabolic ratios and 100% to 150% increase in maximum metabolic ratios in the MS lesions compared with the lowest resolution (32 × 32), while maintaining good spectral quality (signal-to-noise ratio >12, Cramér-Rao lower bounds <20%) and measurement time of 6 minutes. There were 83% of MS lesions that showed increased myo-inositol/N-acetylaspartate with the 100 × 100 resolution, but only 66% were distinguishable with the 64 × 64 resolution and 35% with the 32 × 32 resolution. CONCLUSIONS: Ultra-high-resolution MRSI (~2 × 2 × 8 mm voxel volume) can detect metabolic alterations in MS, which cannot be recognized by conventional MRSI resolutions, within clinically acceptable time.
Authors: Michal Považan; Gilbert Hangel; Bernhard Strasser; Stephan Gruber; Marek Chmelik; Siegfried Trattnig; Wolfgang Bogner Journal: Neuroimage Date: 2015-07-22 Impact factor: 6.556
Authors: Antoine M Klauser; Oliver T Wiebenga; Anand Jc Eijlers; Menno M Schoonheim; Bernard Mj Uitdehaag; Frederik Barkhof; Petra Jw Pouwels; Jeroen Jg Geurts Journal: Mult Scler Date: 2017-04-13 Impact factor: 6.312
Authors: Christian Langkammer; Tian Liu; Michael Khalil; Christian Enzinger; Margit Jehna; Siegrid Fuchs; Franz Fazekas; Yi Wang; Stefan Ropele Journal: Radiology Date: 2013-01-11 Impact factor: 11.105
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Richard Imrich; Miroslav Vlcek; Adela Penesova; Zofia Radikova; Andrea Havranova; Monika Sivakova; Pavel Siarnik; Branislav Kollar; Tomas Sokolov; Peter Turcani; Eva Heckova; Gilbert Hangel; Bernhard Strasser; Wolfgang Bogner Journal: Clin Auton Res Date: 2021-03-04 Impact factor: 4.435
Authors: Stanislav Motyka; Philipp Moser; Lukas Hingerl; Gilbert Hangel; Eva Heckova; Bernhard Strasser; Korbinian Eckstein; Simon Daniel Robinson; Benedikt A Poser; Stephan Gruber; Siegfried Trattnig; Wolfgang Bogner Journal: Magn Reson Med Date: 2019-04-01 Impact factor: 4.668
Authors: Andrew A Maudsley; Ovidiu C Andronesi; Peter B Barker; Alberto Bizzi; Wolfgang Bogner; Anke Henning; Sarah J Nelson; Stefan Posse; Dikoma C Shungu; Brian J Soher Journal: NMR Biomed Date: 2020-04-29 Impact factor: 4.044
Authors: Tomas Horak; Magda Horakova; Alena Svatkova; Zdenek Kadanka; Petr Kudlicka; Jan Valosek; Tomas Rohan; Milos Kerkovsky; Eva Vlckova; Zdenek Kadanka; Dinesh K Deelchand; Pierre-Gilles Henry; Josef Bednarik; Petr Bednarik Journal: J Neurotrauma Date: 2021-11-01 Impact factor: 5.269